Key Takeaways QTIH collaborates with Olea Medical to integrate analytics and visualization into its cloud platform.Shares of QTIH jumped 8.3% after the news and have outperformed the industry and S&P 500 over six months.The integration supports multimodality breast imaging, advanced analytics and cloud delivery.QT Imaging Holdings, Inc. (QTIH) recently announced a collaboration with Olea Medical aimed at enhancing visualization, quantitative analytics and multimodality integration across its cloud imaging p ...

Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Karim Boussebaa as Chief Executive Officer of the Group. Meeting today, Guerbet’s Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Mr. Karim Boussebaa as Chief Executive Officer. This appointment will take effect on ...

Chair of Lumexa Imaging's Center for Quality will serve as the Radiological Society of North America's board liaison for government relations RALEIGH, N.C., Jan. 28, 2026 /PRNewswire/ -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, is proud to recognize Jennifer L. Kemp, MD, Chair of Lumexa Imaging's Center for Quality, has been elected to the Board of Directors of the Radiological Society of North America (RSNA). "Dr. Kemp's election to the RSNA Boar ...

Funding will scale hospital deployments for groundbreaking CT:VQâ"¢ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more LOS ANGELES and MELBOURNE, Australia, Jan. 26, 2026 /PRNewswire/ -- 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its c ...

Core Insights - Polarean is expanding its Xenon MRI platform into cardiopulmonary drug development through a multi-center study focused on pulmonary hypertension patients with interstitial lung disease (PH-ILD) [1][2] Group 1: Study Overview - The study is funded by a leading cardiopulmonary pharmaceutical company and aims to evaluate an inhaled therapy using Xenon MRI-derived biomarkers [2] - The design captures both acute and chronic treatment effects, quantifying changes in lung ventilation, gas diffusion, pulmonary capillary blood volume, and microvascular hemodynamics [4][5] Group 2: Technology and Innovation - Xenon MRI is unique as it directly measures the pulmonary capillaries, an area previously considered a "silent zone" in lung function assessment [3][28] - The technology allows for noninvasive, radiation-free imaging, providing insights into cardiopulmonary physiology at the site of drug delivery [5][8] Group 3: Clinical Implications - The study aims to clarify the local pulmonary effects of inhaled therapies, differentiating them from systemic mechanisms [7] - There is a significant need for better tools to detect and monitor pulmonary vascular involvement in PH-ILD, which affects tens of thousands of patients in the U.S. [9][10] Group 4: Market Position and Future Prospects - Polarean's collaboration with VIDA Diagnostics enhances its capabilities in centralized imaging operations and advanced biomarker analysis [2] - The use of Xenon MRI can accelerate clinical development, potentially saving time and costs while providing novel biomarkers for pulmonary vascular and interstitial disease [8][12]

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026. From a clinical perspective, I have been impressed by the image quality delivered by the ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - Shares of GE HealthCare Technologies experienced a decline following a bearish call from UBS [1]

GE HealthCare CEO Peter Arduini has highlighted the company’s disciplined approach to M&A in order to “fill gaps and add tuck-ins” to its portfolio, while also operating as a company that is well-positioned to advance its portfolio through organic investment and product development. Arduini reflected on the approach, using the company’s recent acquisition of medical imaging software provider Intelerad to contextualise his views, at this year’s J.P. Morgan Healthcare Conference in San Francisco, held from ...

Core Insights - The study published in CHEST demonstrates that structural and functional pulmonary MRI, particularly Xenon MRI, provides significant predictive insights for pulmonary exacerbations in cystic fibrosis patients beyond traditional pulmonary function tests [1][2][4] Company Overview - Polarean is a commercial-stage medical imaging technology company focused on advancing functional MRI of the lungs, utilizing hyperpolarized Xenon 129 as a contrast agent for non-invasive lung function assessment [7] - The company aims to address critical needs in respiratory healthcare by providing tools to visualize lung function, including ventilation, diffusion, and perfusion, in areas previously considered "silent zones" [7] Study Findings - The study analyzed data from 106 cystic fibrosis patients, revealing that Xenon MRI ventilation defect percent (VDP) is independently associated with future exacerbation risk, even in patients with normal spirometry results [2][3] - Patients with abnormal VDP exhibited nearly three times the rate of exacerbations compared to those with normal ventilation, highlighting the importance of detecting regional functional changes in the lungs [3][4] Clinical Implications - The findings underscore the potential of Xenon MRI to enhance clinical management and monitoring strategies for cystic fibrosis, which could lead to improved patient outcomes and cost containment in healthcare [4][5] - The ability to identify patients at increased risk for exacerbations is crucial, especially as pulmonary exacerbations remain a significant factor in morbidity and long-term disease progression in cystic fibrosis [4][6] Broader Applications - The sensitivity of Xenon MRI to small airway abnormalities suggests its potential utility in other pulmonary diseases, such as asthma and COPD, where similar relationships between VDP and exacerbations have been observed [5]